BioSpace News Archive

Baxter International Inc. (NYSE:BAX), a leader in patient monitoring, physical assessment and vision screening products, announced the findings of an observational study on data from the Starling Registry.

Petros Pharmaceuticals, Inc., a leading provider of therapeutics for men’s health, provides positive results from its over-the-counter draft label comprehension study for its erectile dysfunction drug STENDRA, which demonstrate understanding of the messages therein.

ABK Biomedical, Inc., an innovative, clinical-stage medical device company dedicated to the research, development and commercialization of advanced imageable embolic therapies, announced the first patient treated in ABK’s First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device for the treatment of liver cancers.

Horizon Therapeutics plc announced the kickoff of the second annual global innovation challenge, The Horizon Prize powered by MIT Solve.

BioFlyte, a biodetection company with a revolutionary new class of fieldable biological threat collection, detection, and identification solutions, today announced that it raised $6.1M in new financing led by Cottonwood Technology Fund with additional funding from existing investor Anzu Partners.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the empty capsule material that comprises its pancreatic cancer clinical trial product candidate does not cause systemic toxicity.

Cosmos Holdings, Inc. provided a business update and reported financial results for the year ended December 31, 2021.

Dr. William Dahut has been named Chief Scientific Officer for the American Cancer Society.

The Stem Cell Spaceshot Grant is open to PhD-level scientists and PhD students conducting research in stem cell biology, biophysics, gene editing, cell therapy, and bioproduction engineering.

NemaLife Inc.,a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.